Abstract- Successful new industries are forged in the gap between early-stage technological innovation and unmet technological needs that block new avenues to improving the quality of human life. This principle applies quite aptly to the envisioned industry of normal human cell biomanufacturing. The highly anticipated benefits of regenerative medicine have been delayed by such a technological gap. In all its varied formulations, regenerative medicine has one essential requirement, an adequate supply of normal human tissue cells for therapeutic interventions ranging from repairing debilitating injuries to treating diseases caused by tissue cell defects and deficiencies. However, with a few recent exceptions, the primary source of cells for existing and emerging regenerative therapies is direct harvest of therapeutic tissue cells from normal donors, either living or deceased. Cell supply based on donation is inherently scarce and unreliable. On-demand production of normal human tissue cells is now recognized as the ratelimiting unmet technological need that stands in the way of progress in regenerative medicine. Three different types of tissue stem cells, distributed (also known as adult), embryonic, and induced pluripotent, have been suggested as the solution for normal human tissue cell biomanufacturing. However, with currently available cell biotechnologies, only distributed stem cells (DSCs) present a realistic solution. Herein, the suitability of DSCs for advancing a new industry of normal human cell biomanufacturing is considered with respect to their pluripotent counterparts, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Read More.
Related Posts
Recent Posts
- Asymmetrex® Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at UMassAmherst
- Asymmetrex’s Introduction of Online Calculators for Determination of the Dosage of Therapeutic Stem Cells Announced as a Reformation in Stem Cell Science and Medicine
- Asymmetrex® Interviewed by Tech Company News About Plans to Introduce Online Rapid-Counting Calculators for Quantifying Therapeutic Tissue Stem Cells
- Asymmetrex®’s Kinetic Stem Cell (KSC) Counting Technology is Featured in the Parent’s Guide to Cord Blood Foundation® June Newsletter
- Asymmetrex® Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine Biomanufacturing
Tags
- Adult Stem Cells
- Announcements
- Asymmetrex News
- Biotechnology
- Immortality and Stem Cells
- Industry News
- Interview
- Kinetic Stem Cell Counting
- Online Workshop
- Regenerative Medicine
- Reports
- Stem Cell Counting
- Stem Cell Information
- Stem Cell Injections
- Stem Cell Medicine
- Stem Cell Research
- Stem Cell Technology
- Stem Cell Toxicology
- Webinar
Leave a Reply